$0.53
7.00% day before yesterday
Nasdaq, Sep 06, 10:12 pm CET
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Stock price

$0.53
-0.49 48.15% 1M
-0.92 63.52% 6M
-0.85 61.67% YTD
-3.27 86.08% 1Y
-11.12 95.46% 3Y
-63.84 99.18% 5Y
-23.87 97.83% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.04 7.00%
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

Key metrics

Market capitalization $101.94m
Enterprise Value $222.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.24
P/S ratio (TTM) P/S ratio 4.69
P/B ratio (TTM) P/B ratio 0.25
Revenue growth (TTM) Revenue growth 322.60%
Revenue (TTM) Revenue $21.73m
EBIT (operating result TTM) EBIT $-331.08m
Free Cash Flow (TTM) Free Cash Flow $-280.57m
Cash position $183.18m
EPS (TTM) EPS $-0.74
P/E forward negative
P/S forward 1.01
EV/Sales forward 2.21
Short interest 22.79%
Show more

Is bluebird bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a bluebird bio, Inc. forecast:

3x Buy
30%
6x Hold
60%
1x Sell
10%

Analyst Opinions

10 Analysts have issued a bluebird bio, Inc. forecast:

Buy
30%
Hold
60%
Sell
10%

Financial data from bluebird bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
22 22
323% 323%
100%
- Direct Costs 25 25
44% 44%
116%
-3.45 -3.45
60% 60%
-16%
- Selling and Administrative Expenses 145 145
9% 9%
666%
- Research and Development Expense 179 179
34% 34%
822%
-327 -327
25% 25%
-1,503%
- Depreciation and Amortization 4.38 4.38
-
20%
EBIT (Operating Income) EBIT -331 -331
25% 25%
-1,524%
Net Profit -91 -91
80% 80%
-420%

In millions USD.

Don't miss a Thing! We will send you all news about bluebird bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

bluebird bio, Inc. Stock News

Positive
Seeking Alpha
10 days ago
Investment activity in July focused on Business Development Companies, with $2,000 added to the market. Adjusted dividend income in July of $709, up 19% Y/Y and down 4% sequentially. Main picks included Blackstone Secured Lending, Ares Capital and Owl Rock Capital.
Neutral
Business Wire
15 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received notices (the “notices”) on August 20, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the “Q1 2024 Form 10-Q”) and June 30, 2024 (the “Q2 2024 Form 10-Q”), it i...
Neutral
Seeking Alpha
24 days ago
bluebird bio, Inc. (NASDAQ:BLUE ) Q2 2024 Results Conference Call August 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of Investor Relations Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer James Sterling - CFO Conference Call Participants Jack Allen - Baird Eric Joseph - JPMorgan Gena Wang - Barclays Jeff Hung - Morgan Stanley Luca Issi - RBC Cap...
More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Obenshain
Founded 1992
Website www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today